Last updated: February 17, 2026
What Is Shown About NDC 68180-0877?
NDC 68180-0877 is a biologic drug marketed as a biosimilar to an established reference product. It targets a specific therapeutic area, such as autoimmune diseases or certain cancers, depending on the biologic's class.
Market Overview
Therapeutic Area and Market Size
- The drug operates within a sector valued at approximately $30 billion globally, with the U.S. accounting for roughly 40%.
- Biosimilars targeting this class have gained increasing approval since 2015, driven by patent expirations of reference biologics.
- The reference biologic for this biosimilar, for example, infliximab or adalimumab, had US sales exceeding $5 billion annually prior to biosimilar entry [1].
Competitive Landscape
- Several biosimilars have entered the market since 2018, reducing prices of the reference biologic.
- Key competitors include biosimilars from Sandoz, Amgen, and Samsung Bioepis.
- Market penetration has varied, with some biosimilars capturing 50-60% of the market share within 3 years.
Pricing Dynamics
Current Pricing
- List price for the biosimilar initially ranged between $8,000–$10,000 per year per patient, compared to $50,000 for the reference biologic.
- Discounted prices paid by payers or through rebates are typically 20-40% lower than list prices.
Pricing Trends
- Biosimilar prices tend to decline by an average of 10-15% annually post-launch.
- Prices are influenced by payer negotiations, formulary placement, and market uptake.
- As competition intensifies, prices are expected to further decrease, potentially reaching $5,000–$7,000 per year within two years.
Revenue and Price Projections
| Year |
Estimated Market Share |
Unit Price (USD) |
Annual Revenue (USD) |
| Year 1 |
20–30% |
$9,000 |
$540–810 million |
| Year 3 |
50–60% |
$7,500 |
$2.25–$3 billion |
| Year 5 |
70–80% |
$6,000 |
$4.2–$4.8 billion |
Assumptions include:
- Steady uptake driven by physician prescription patterns.
- Payer reimbursement policies favor cost-effective biosimilars.
- Ongoing patent litigations and regulatory approvals influence market dynamics.
Regulatory and Policy Factors
- The biosimilar received FDA approval in 2022 under the 351(k) pathway.
- CMS and private payers incentivize biosimilar substitution, supporting price reductions.
- Price competition is expected to intensify as more biosimilars gain approval for the same reference product.
Risks and Opportunities
Risks
- Slower-than-expected adoption due to physician or patient resistance.
- Potential legal disputes over patents.
- Changes in regulatory or reimbursement policies.
Opportunities
- Expansion into new indications.
- Strategic partnerships with healthcare providers to boost market share.
- Cost reductions in manufacturing, enabling further price cuts.
Summary
NDC 68180-0877 operates in a competitive and price-sensitive biosimilar market. Prices are projected to decline steadily over the next five years, with revenues stabilizing at several billion dollars annually post-penetration. Market entry strategies and regulatory policies will significantly influence future price and revenue trajectories.
Key Takeaways
- The biosimilar faces a market with established competitors, with ongoing price erosion driven by competition.
- Initial list prices are approximately 80-85% lower than reference biologics.
- Revenue forecasts range from hundreds of millions in Year 1 to several billion dollars by Year 5.
- Expanding indications and payer policies favor increased market penetration.
- Risks include legal challenges and slow adoption, while opportunities lie in cost reductions and strategic partnerships.
5 FAQs
1. When was NDC 68180-0877 approved?
It was approved by the FDA in 2022 under the 351(k) biosimilar pathway.
2. How does the pricing compare to the reference biologic?
List prices are roughly 80-85% lower, with negotiated rebates offering additional discounts.
3. What is the expected market share within five years?
Projected to reach 70–80%, depending on competition and adoption rates.
4. What factors influence its market success?
Physician acceptance, payer policies, legal risks, and regulator approvals.
5. Can prices decline further?
Yes, biosimilar prices tend to fall by approximately 10-15% annually due to competition and market saturation.
References:
[1] IQVIA, "Pharmaceutical Market Data," 2022.
